Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 4/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735954 | 0.85 | SIGMAR1 (0.40) | SIGMAR1OPRM1CDK4OPRL1GRM5 | |
| SCHEMBL736974 | 0.85 | SIGMAR1 (0.38) | SIGMAR1OPRM1CDK4OPRL1GRM5 | |
| SCHEMBL736045 | 0.85 | CHRNB2 (0.44) | SIGMAR1OPRM1KCNH2OPRL1CHRNB2 | |
| SCHEMBL735996 | 0.83 | SIGMAR1 (0.47) | SIGMAR1OPRM1OPRL1 | |
| SCHEMBL736268 | 0.82 | CDK4 (0.45) | SIGMAR1OPRM1ELANEKCNH2CDK4 | |
| SCHEMBL736972 | 0.82 | OPRL1 (0.43) | SIGMAR1OPRM1KCNH2OPRL1SSTR5 | |
| SCHEMBL736596 | 0.81 | SIGMAR1 (0.46) | SIGMAR1OPRM1KCNH2GRM5CHRNB2 | |
| SCHEMBL736367 | 0.81 | OPRM1 (0.40) | SIGMAR1OPRM1OPRL1 | |
| SCHEMBL4941184 | 0.80 | SIGMAR1 (0.36) | SIGMAR1OPRM1OPRL1CHRNB2CHRNA4 | |
| SCHEMBL735106 | 0.79 | SIGMAR1 (0.39) | SIGMAR1OPRM1OPRL1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | SIGMAR1 11/4885OPRM1 15/4885ELANE 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.